Business Wire (Wed, 8:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,152 people get INCY articles and Market Currents by email alert.
Get email alerts on INCY »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
Business Wire (May 3, 2013)
-
Business Wire (May 2, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 11, 2013)
-
Incyte's Jakafi Is Likely A $1 Billion DrugOhad Hammer • Wed, Feb 27 -
Business Wire (Feb 20, 2013)
-
-
Business Wire (Jan 24, 2013)
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
Incyte's Jakafi Is Likely A $1 Billion DrugOhad Hammer • Wed, Feb 27
-
-
-
-
-
-
-
Incyte: Myelofibrosis Drug Looks PromisingOhad Hammer • Mon, Dec 27, 2010
-
Odds Increase for Approval of Incyte's Myelofibrosis DrugProhost Biotech • Wed, Sep 29, 2010
-
Incyte Extends Losses, Increases RevenueZacks Investment Research • Sun, Feb 21, 2010
-
Cohen's SAC Capital Boosts Passive Stake in Incyte to 6.4%Lon Juricic • Fri, Aug 8, 2008
-
-
-
-
-
-
-
-
-
Hedge Funds Are Buying These 5 Healthcare Stocks With Heavy Short CoveringKapitall • Fri, Nov 30, 2012 -
-
-
-
-
-
-
-
-
4 Mid-Cap Healthcare Stocks With Strong Projected Growth And Analyst BackingZetaKap • Wed, Aug 22, 2012 -
-
-
Incyte's CEO Discusses Q3 2012 Results - Earnings Call TranscriptThu, Nov 1, 2012
-
Incyte's CEO Discusses Q2 2012 Results - Earnings Call TranscriptThu, Aug 2, 2012
-
Incyte's CEO Discusses Q1 2012 Results - Earnings Call TranscriptThu, Apr 26, 2012
-
Incyte CEO Discusses Q3 2011 - Earnings Call TranscriptTue, Nov 1, 2011
-
Incyte Corp. CEO Discusses Q2 2011 Results - Earnings Call TranscriptThu, Jul 28, 2011
-
Incyte CEO Discusses Q4 2010 Results - Earnings Call TranscriptThu, Feb 10, 2011
-
Business Wire (Wed, 8:00AM)
-
Business Wire (May 3, 2013)
-
Business Wire (May 2, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 11, 2013)
-
Business Wire (Feb 20, 2013)
-
Business Wire (Jan 24, 2013)
-
Business Wire (Dec 19, 2012)
-
Business Wire (Dec 10, 2012)
-
Business Wire (Dec 7, 2012)
-
Business Wire (Nov 28, 2012)
-
Business Wire (Nov 19, 2012)
-
Business Wire (Nov 5, 2012)
-
Business Wire (Oct 22, 2012)
-
Business Wire (Oct 9, 2012)
-
Business Wire (Sep 19, 2012)
INCY vs. ETF Alternatives
Company Description
Incyte is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs. We have a broad pipeline with programs focused primarily in the areas of oncology and inflammation. We focus our efforts on clinical programs that we... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Friday, May 3, 6:18 PM
After-hours top gainers, as of 5:30 p.m.: ABFS +16.0%. RNR +3.75%. MSG +3.3%. NCT +3.1%. INCY +3.0%.
After-hours top losers: STM -9%. GRMN -3.6%. BRCD -2.7%. H -2.6%. CPWR -2.1%. Comment! [On the Move] - Thursday, May 2, 7:07 AM Incyte (INCY): Q1 EPS of -$0.12 beats by $0.06. Revenue of $71.1M beats by $2.94M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, May 2, 12:05 AM Notable earnings before Thursday’s open: ABMD, ACOR, ACT, AEE, ANR, ANSS, ARG, ARQL, ATK, AYR, BDBD, BDX, BEAM, BGCP, BZH, CAH, CEVA, CHD, CI, CME, CNP, CPN, CTRX, DIN, DNR, EL, ELNK, FIG, FLY, FNP, FWLT, GEL, GG, GIL, GM, GNRC, GOLD, HAR, HK, HSH, INCY, INGR, IP, IRDM, IT, ITT, K, LF, LQDT, LXP, MDC, MFC, MGI, MGM, MMC, MMP, MWW, NIHD, NNN, NUS, OCN, OGE, OXF, OZM, PCG, PPL, PWR, PXP, RGLD, RNO, SBH, SFY, SHPG, SNI, SPR, SRE, STRA, TEVA, VMC, VRX, WNR, WPX, WWE, XEL Comment! [Earnings]
- Wednesday, May 1, 5:30 PM Notable earnings before Thursday’s open: ABMD, ACOR, ACT, AEE, ANR, ANSS, ARG, ARQL, ATK, AYR, BDBD, BDX, BEAM, BGCP, BZH, CAH, CEVA, CHD, CI, CME, CNP, CPN, CTRX, DIN, DNR, EL, ELNK, FIG, FLY, FNP, FWLT, GEL, GG, GIL, GM, GNRC, GOLD, HAR, HK, HSH, INCY, INGR, IP, IRDM, IT, ITT, K, LF, LQDT, LXP, MDC, MFC, MGI, MGM, MMC, MMP, MWW, NIHD, NNN, NUS, OCN, OGE, OXF, OZM, PCG, PPL, PWR, PXP, RGLD, RNO, SBH, SFY, SHPG, SNI, SPR, SRE, STRA, TEVA, VMC, VRX, WNR, WPX, WWE, XEL Comment! [Earnings]
- Monday, April 29, 8:25 AM Incyte (INCY) is set to receive a $25M milestone payment from Novartis (NVS) as a Phase II clinical trial for INC280 formally gets underway. NVS has exclusive development and commercialization rights to the compound. (PR) Comment! [Healthcare]
- Monday, March 18, 11:59 AM Brean Murray defends Incyte (INCY -8.3%) following the news that a UK patient taking Jakafi developed PML. Brean says the patient had been taking the drug for only three months, and is not likely related to the infection. Analyst Jonathan Aschoff notes that, "Even Tysabri had no cases of PML within the first eight months of therapy." Comment! [Healthcare, On the Move]
- Monday, March 18, 11:35 AM Incyte (INCY -7.9%) slips today after disclosing that a UK patient taking its bone-marrow drug Jakafi died of a rare brain infection. The company says it's unclear whether Jakafi caused the infection and that it's the only reported case among nearly 10K people who've taken the drug. 1 Comment [Healthcare, On the Move]
-
Monday, March 18, 9:10 AM
Premarket gainers: FU +19%. PRWT +9%. GALE +7%. CLSN +7%.
Losers: AMBO -15%. INCY -12%. FBN -11%. JVA -8%. NBG -6%. ING -6%. NVO -5%. Comment! [On the Move] - Thursday, February 14, 7:06 AM Incyte (INCY): Q4 EPS of $0.14 beats by $0.16. Revenue of $113.8M beats by $21.77M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, February 14, 12:05 AM Notable earnings before Thursday’s open: ABB, ABX, ALXN, ANR, APA, BGCP, BWA, CAB, CRIS, CVE, DISCA, DTV, DVA, DWRE, ECA, GELG, GM, GNC, GNRC, INCY, JAH, LNT, LUFK, MFA, NGLS, NRF, O, OAK, PDS, PEP, PPL, REGN, SHPG, STRA, TAP, UTHR, VMC, WM, ZIP Comment! [Earnings]
- Wednesday, February 13, 5:30 PM Notable earnings before Thursday’s open: ABB, ABX, ALXN, ANR, APA, BGCP, BWA, CAB, CRIS, CVE, DISCA, DTV, DVA, DWRE, ECA, GELG, GM, GNC, GNRC, INCY, JAH, LNT, LUFK, MFA, NGLS, NRF, O, OAK, PDS, PEP, PPL, REGN, SHPG, STRA, TAP, UTHR, VMC, WM, ZIP Comment! [Earnings]
- Monday, January 14, 3:12 PM Incyte (INCY +6.8%) gains today after Lazard Capital upped the shares to Buy earlier with a $25 price target. Lazard says that INCY's myelofibrosis treatment Jakafi is now being prescribed by some doctors to patients with less-severe cases of the bone-marrow disorder, after a reluctance to treat earlier-stage patients in the past. The firm attributes the change to INCY teaching physicians to titrate the Jakafi dose, which leads to fewer side effects and improves comfort. Comment! [Healthcare, On the Move]
- Monday, December 10, 2012, 7:45 PM Incyte (INCY) presented several analyses today from clinical studies of ruxolitinib, an oral Janus kinase inhibitor that's FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis. Long-term results show that patients treated with the drug had improved survival rates over placebo and best available therapy. Additionally, data from ongoing trials suggest that long-term treatment may be an effective therapy for patients with polycythemia vera - a bone marrow disease that leads to an abnormal increase in the number of blood cells - as well. Comment! [Healthcare]
- Tuesday, November 13, 2012, 4:25 PM Eli Lilly (LLY) and Incyte (INCY) announce positive results from ongoing Phase IIb studies of baricitinib in patients with rheumatoid arthritis who had an inadequate response to treatment with methotrexate. Additionally, MRI technology was used in a sub-study to examine the effect of baricitinib on joint erosion and other markers of structural changes in and around the joint, which showed statistically significant improvement in both the Total Inflammation Score and the Total Joint Damage Score compared with placebo at 12 weeks. LLY +0.8%, INCY -0.9% AH. 2 Comments [Healthcare]
-
Thursday, November 1, 2012, 6:48 PM
After-hours top gainers, as of 6:30 p.m.: TRIP +17.3%; PCLN +8.5%; LNKD +7.8%; OWW +5.3%; YPF +4.4%.
After-hours top losers: ACTV -25.1%; EDMC -8.4%; GES -7.3%; MELI -6.4%; INCY -6%. Comment! [On the Move] - Thursday, November 1, 2012, 7:22 AM Incyte (INCY): Q3 EPS of -$0.17 beats by $0.04. Revenue of $60.5M in-line. (PR) Comment! [Earnings, Healthcare]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.